Alere Toxicology Services, INC

Alere Toxicology Services, INC was paid $7.83M by Medicaid between Jan 2018 and Sep 2019, across 38 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 46% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Virginia

Rank by total paid#5 of 78

Median peer was paid$37K

This provider vs. median213×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	265,131	$5.62M
2019	109,411	$2.21M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	46%	98,998	59,738	$3.63M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	30%	84,129	55,223	$2.35M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	11%	13,475	9,890	$887K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	3.5%	3,215	1,776	$276K
80348		1.3%	19,960	11,772	$100K
80362		1.0%	15,639	8,170	$80K
80355		<1%	17,751	12,472	$70K
80321		<1%	11,960	6,688	$50K
80346		<1%	11,346	7,983	$42K
80324		<1%	10,437	6,714	$33K
80349		<1%	8,960	5,667	$29K
80354		<1%	10,380	7,320	$27K

26 more codes

80361		<1%	6,908	$24K
80366		<1%	6,360	$24K
80323		<1%	3,192	$22K
80358		<1%	10,966	$19K
80365		<1%	5,804	$18K
80356		<1%	4,116	$16K
80325		<1%	2,139	$15K
80373		<1%	3,073	$14K
80369		<1%	2,725	$14K
80360		<1%	3,660	$11K
80368		<1%	1,896	$10K
80336		<1%	1,207	$10K
80353		<1%	3,603	$9K
80352		<1%	1,760	$8K
80332		<1%	1,380	$6K
80359		<1%	1,761	$6K
80338		<1%	1,093	$5K
80345		<1%	1,294	$5K
80342		<1%	837	$4K
80335		<1%	470	$4K
80371		<1%	1,453	$4K
83992		<1%	1,495	$4K
80363		<1%	517	$3K
80372		<1%	87	$811.99
80367		<1%	390	$710.75
80339		<1%	106	$500.82

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSCOGGINS, CHRISTOPHER (PRESIDENT)

Parent organizationALERE INC

Same official

Other billing entities under SCOGGINS, CHRISTOPHER

Full network →

Provider	Location	Paid
Alere Home Monitoring, INC.	Livermore, CA	$2.47M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.